• Managing Partner Eric Chow spoke at the seminar "Go Global Through Innovation · Setting Sail from Hong Kong: Global Expansion Pathways for Mainland Enterprises"

    Tongshang Hong Kong Managing Partner Eric Chow, spoke today at the seminar "Go Global Through Innovation · Setting Sail from Hong Kong: Global Expansion Pathways for Mainland Enterprises (创科出海·香港启航:内地企业全球化路径)", held at Deloitte Hong Kong office.

    Co-hosted by Deloitte China and CityU HK Tech 300, the event brought together business leaders, innovators, and policymakers to discuss how Hong Kong can serve as a launchpad for mainland enterprises pursuing global growth.

    Eric joined a distinguished panel on "Navigating the Key Steps to a Successful Hong Kong Listing," with fellow industry professionals sharing their practical insights on IPO readiness, regulatory considerations, and the factors that contribute to a successful listing journey.

    The seminar also featured keynote addresses from representatives of the HKSAR Government's "Go Global Task Force," including members from the Innovation, Technology and Industry Bureau (ITIB), Hong Kong Exchanges and Clearing Limited (HKEX), and the Office for Attracting Strategic Enterprises (OASES), offering valuable perspectives on Hong Kong's role in supporting companies' international ambitions.

    See More
  • Tongshang Hong Kong once again contributes to the Second Series of “Collection of Success Stories: Hong Kong's Professional Services Supporting Chinese Mainland Enterprises Going Global.”

    We are delighted to share that the Department of Justice has published the Second Series of “Collection of Success Stories: Hong Kong's Professional Services Supporting Chinese Mainland Enterprises Going Global.”

    Tongshang Hong Kong is honoured to once again contribute to this important initiative, which highlights Hong Kong’s unique role as a trusted international hub for professional services.

    Featuring over 160 case studies, the publication highlights how Hong Kong’s professional services sectors support Mainland enterprises at every stage of their international expansion. It also emphasizes the value of engaging legal and other professional advisers early in the project planning process to enable effective risk management from the outset.

    We look forward to continuing our collaboration with the Department of Justice and fellow professional bodies to further strengthen Hong Kong’s professional services platform and support enterprises in achieving their global ambitions.

    See More
  • Tongshang Hong Kong continues our support for the CBLJ Forum Beijing 2026

    Tongshang Hong Kong was delighted to continue our support for the CBLJ Forum Beijing 2026, in which our partner Brandon Chow moderated an insightful panel discussion on “Navigating Hong Kong IPOs: Practical Strategies for Success”, alongside industry experts from Insilico Medicine AI Technology, Investment Banking Department at Guotai Haitong Securities and Lightelligence Inc.

    The session sparked insightful discussions on the challenges facing Hong Kong’s capital markets today. Speakers shared strategic insights on how issuers can optimize document quality, foster closer collaboration with sponsors, and seamlessly navigate regulatory review processes to safeguard their listing schedules.

    Thank you to China Business Law Journal (CBLJ) for hosting another exceptional event, and to our fellow panellists for a thoroughly engaging discussion!

    See More
  • Tongshang & Tongshang HK jointly represented Shaanxi Micot Pharmaceutical Technology Co Ltd in its HK IPO

    Tongshang and Tongshang Hong Kong represented the Joint Sponsors and Underwriters of Shaanxi Micot Pharmaceutical Technology Co Ltd (“MICOT PHARMA-B”, Stock Code: 02335.HK) in its global offering and listing on the Main Board of the Stock Exchange of Hong Kong Limited. The gross proceeds of the global offering is HKD 1.1 billion. CCB International Capital Limited and China Merchants Securities (HK) Co., Limited acted as the Joint Sponsors for this listing.

    MICOT PHARMA-B, is a China-based biopharmaceutical company principally engaged in the research and development of innovative drugs. The Company focuses on the research and development of new drugs for the treatment of cardiovascular and cerebrovascular diseases, metabolic disorders, and inflammatory pain-related diseases. It is also the first innovative drug developer focused on a peptide-based technology platform to list under Chapter 18A of the Hong Kong Listing Rules, and the first Chapter 18A biotech company from Northwest China to go public.

    Tongshang Hong Kong team was led by Partners Ning Liu and Angela Zhang, Counsel Dai Mengyi, Associates June Zhu and Dandan Zhu, Legal Consultants Lexie Wang, Sally Shi, Luca Luo and Cora Lam.

    See More